# Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients

> **NCT00056641** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 328 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** tipranavir
- **DRUG:** ritonavir
- **DRUG:** saquinavir
- **DRUG:** amprenavir
- **DRUG:** lopinavir

## Key facts

- **NCT ID:** NCT00056641
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02-18
- **Primary completion:** 2004-01-27
- **Final completion:** —
- **Target enrollment:** 328 (—)
- **Last updated:** 2023-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00056641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00056641, "Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00056641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*